Keep your eyes on $NBIO. This play is just heating up, just needs awreness. No dilution, clean level 2, and 2 cancer drugs in clinical trials. Low float, low monthly burn rate. This is a gem.
$MJNA Medical Marijuana (OTCPK:MJNA +2.1%) Q1 revenue growth of more than 190% Y/Y exceeding $10.5M.
Total gross profits for the quarter increased more than 30% to $3.3M.
Wholly-owned subsidiary Kannaway revenues increased more than 325% to $7.5M.
"In Q1 2018, we had the best revenue quarter in the history of our Company," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We're excited that, with the help of our investors, spokespeople and customers, we've experienced tremendous growth and the company is positioned well for continued explosive expansion."
News 
Market Data 
Discover 
AI
